Cel Sci Corporation (CVM)

[Tonymd]

There was still 1 hurdle after Cel-Sci released their Phase 3 data for MultiKine. Because MK did not work with Chemotherapy it was unclear how to "write the (prescription) label" in pharma speak. By identifying the PD-L1 protein reaction this issue was solved. Simply put, anyone on a single doctor's visit can receive a routine and established P.E.T. scan and biopsy and know within 24 hours if they can/should receive MultiKine. The patients prescribed MK will have: 1) A 73% chance of living 5 years or longer. 2) The risk of death is cut by more than half at 5 years. 3) A large percentage of MK recipients will see a reduction in tumor size and stage (II, III, or IV) of the cancer. No new test or cost are required. Regulatory conditional approval pathways now exist for reasons exactly like MK. The toxicity profile of MK is nearly perfect.